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Biology and Clinical Relevance of Human Natural Killer Cells 
By Michael J. Robertson and Jerome Ritz 
ATURAL KILLER (NK) cells comprise  10% to 15%  N  of  human peripheral blood  lymphocytes  (PBL) and 
most  have  the morphology  of  large granular lymphocytes 
(LGL).’s2  NK  cells are  defined functionally by their ability to 
lyse target cells without  deliberate prior  sensitization  and 
without  restriction  by  major  histocompatibility  (MHC) 
 antigen^.^.^  NK activity was  first  described  in  the 1970s, 
when it was observed that lymphocytes freshly isolated from 
normal unimmunized hosts could lyse allogeneic tumor cell 
Subsequent studies showed  that such NK activity 
was mediated by “null cells,” lymphocytes devoid of charac- 
teristic T-cell and B-cell surface antigens.’*’’ Use of  mono- 
clonal  antibodies  (MoAbs)  and  techniques  of  molecular 
biology have allowed  the unequivocal  identification of NK 
cells as a discrete population of cytolytic effectors (Table 1). 
NK cells have been implicated in several activities in vivo, 
including  destruction  of  tumor  cells,  resistance  to  viral 
infections, and regulation of hemat~poiesis.~.’’  Although NK 
activity was originally described in the mouse and in humans, 
effectors resembling murine and human NK  cells have been 
isolated  from  many vertebrates,  including  monkeys,  rats, 
hamsters, cats, dogs, birds, and fish.”  Furthermore, NK-like 
effectors  have  been  described  in  animals  as primitive  as 
starfish  and  Because  the  latter  do  not 
possess cells analogous to vertebrate T and B lymphocytes, 
the  development  of  NK-like  activity  probably  preceded 
evolution of the adaptive immune ~ystem.”.’~  Although NK 
cells can be isolated from spleen, bone marrow, liver, lung, 
and  the present  review will focus on peripheral 
blood NK  cells. A summary of all aspects of NK  cell biology 
is  beyond  the scope  of  this  article; other  recent  reviews 
discuss areas not considered here.4,5,246 
SURFACE ANTIGENS OF  HUMAN NK  CELLS 
NK cells can be partially purified by discontinuous Percoll 
density gradient centrifugation.’**  However, only 60% to 80% 
of Percoll-enriched  large granular lymphocytes  (LGL) ex- 
hibit  NK activity or characteristic NK cell  surface anti- 
gens,2.15,16 and some NK cells do not  demonstrate typical 
LGL morphology.”  Obtaining highly purified populations of 
NK cells has generally required positive  selection by  flow 
cytometry or immune rosette techniques,  or negative selec- 
tion by elimination of other lymphocyte subsets using comple- 
ment  lysis  or  immunomagnetic  beads.  In  the  quest  for 
“NK-specific”  antigens, the reactivity  of  many monoclonal 
antibodies (MoAbs) with NK  cells has been determined. No 
single  surface  antigen  described  to  date  unambiguously 
identifies  all  human  NK cells.  The  antigens  used  most 
extensively  as NK cell  “markers”  for  clinical and  basic 
research purposes are CD56 (NKH-1, Leu-19) and CD16 
(Fcr  R 111). The CD56 antigen is expressed by virtually all 
human  peripheral  blood  cells  capable  of  non-MHC-re- 
stricted cytoto~icity.4*’~-’~  It appears to be identical to the 
neural cell adhesion molecule (NCAM),20  a well-character- 
ized  structure mediating  homotypic adhesive  interactions 
between  neural and muscle  NCAM has at least 
three isoforms, generated by differential splicing of the RNA 
transcript from a single gene located on human chromosome 
1  1  .21 The core polypeptide of the CD56 antigen appears to be 
the 140 Kd isoform of NCAM?’  which  is variably glyco- 
sylated and sialylated to produce mature species with molec- 
ular weights  ranging from  175 to 220 Kd.’’x2’  The CD56 
antigen itself appears not to participate directly in NK  killing 
of  most  target cells,”~’’ although a  recent report suggests 
that CD56 can mediate homotypic adhesion of NK cells to 
CD56+ tumor cell lines.23 
A small fraction (4%)  of normal peripheral blood lympho- 
cytes (PBL) expresses both CD56 and CD3  and is capable of 
non-MHC-restricted cytotoxi~ity.”~~~  CD3 is  an invariant 
complex associated with the T-cell receptor (TCR); CD3 is 
not present on NK  cells, which do not rearrange TCR genes 
nor express T-cell receptor heterodimer~.~’.~~  Some  investiga- 
tors have proposed  the term “non-MHC-restricted  T cells” 
be  used  to  describe these  CD56-t  CD3+   lymphocyte^.^ 
Furthermore, CD3  + human thymocytes cultured in interleu- 
kin 2 (IL-2) can be induced to express CD56 in parallel with 
their acquisition of NK a~tivity.~’*~’  Although CD56 expres- 
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Table 1.  Characteristics of NK Cells and Other Cytolytic Effectors 
NK  T 
Cells  Cells 
Surface antigens* 
CD2  70-90  >95 
CD3  0  >95 
CD8  30-40  30-40 
CD1 lb  80-90  10-15 
CD15  t5  <5 
CD16  80-90  t5 
CD56  >95  t5 
Monocytes 
<5 
0 
t5 
>  90 
60-80 
10-158 
t5 
Neutrophils 
<5 
0 
t5 
>90 
>95 
>95 
t5 
Functional  attributest 
ADCC  Yes  No  Yes  Yes 
NK activity$  Yes  Noli  No  No 
Phagocytosis  No  No  Yes  Yes 
Immunologic 
memory  No  Yes  No  No 
Proliferative 
capabilitv  Yes  Yes  No  No 
*Approximate % of cells from each lineage that express antigen; data 
summarized from references 4, 5,  18, 29, 31, 36, 38, 49,  58-61, 78, 
and 232. 
tsummarized from references 3-5,  10, 24, 30, 56, 58, 59, 61, 108, 
and 246. 
$NK activity, spontaneous antibody-independent  non-MHC-restricted 
cytotoxicity. 
8CD 16 is also expressed by most cultured or activated  monocyte^.^^^^* 
IlWith the exception of  the  small fraction  (t5%)  of  T cells which 
express CD56.'7.24 
sion is characteristic of  lymphoid effectors that kill target 
cells in an MHC-unrestricted  fashion, not all CD56+ cells 
are typical NK cells. 
cells" or are a discrete NK cell subset with unique functional 
attributes is  presently unclear.  There are thus  limitations 
inherent in the use of either CD56 or CD16 alone to identify 
NK cells. However, CD56 appears to identify all lympho- 
cytes possessing NK activity, and NK cells can at present be 
best defined phenotypically as CD56+ CD3 -  lymphocytes. 
The CD57 (HNK-1, Leu-7) antigen has also been used in 
the past  as an NK cell marker.34 This  110 Kd antigen is 
expressed by  only  -50%  to 60%  of  peripheral  blood  NK 
Furthermore, only -50% of  PBL that express 
CD57  are  actually  NK  cells,  the  remainder  apparently 
representing T lympho~ytes.~~'~~  Finally, cell sorting based on 
CD57 antigen expression does not isolate NK cells as reliably 
as  does  sorting  based  on  the  expression  of  CD16  or 
CD56.18,29-35337  Thus studies using only CD57 to identify NK 
cells must be interpreted with caution. 
Other cell surface antigens are characteristically but not 
uniformly expressed by human NK cells (Table 2). CD2 (the 
T11 sheep erythrocyte receptor)  and  CD7 are present  on 
-80%  of  NK  cells  and  CD8  on  30%  to  40%  of  NK 
cells.4.1 8.29.36 The density of CD8 antigen on NK cells is lower 
than that on T  cell^,^^,^^ however, and most CD8+ NK cells 
express CD8a/CD8a homodimers rather than the CD8a/ 
CD8p  heterodimers  prevalent  on  suppressor/cytotoxic  T 
~ells.~~,~~  Very few, if any, NK cells express the CD4 glyco- 
Approximately 80%  of NK cells express CD1  l b 
(Mol,  Macl, C3bi receptor) and 30%  to 60% express CDl  IC 
(p150, 95); other myelomonocytic antigens, such as CD14 
and CD15, are not present on NK ce11s.4~18s29~36~78  Similarly, 
NK cells do not express B-cell antigens such as CD19, CD20, 
and CD22.'8,29,36 
cells.3  1.35-37.232 
Most  CD56+  PBL  also  express  CD16,  a  low  affinity 
receptor for the Fc region of  IgG.'7,29330  CD16 expression is 
not limited to NK cells, however (Table  1). Furthermore, 
GENERATION OF CLONAL NK CELL LINES 
Even  highly  purified  polyclonal  NK  cell  preparations 
about 10% of  normal peripheral blood NK cells are CD16- 
but  exhibit high density surface expression of  CD56.17,3'-33 
Whether  these CD56"b"gh'"  CD16 - lymphocytes represent 
precursors  of  the more  numerous  CD56"dim"  CD16+  NK 
contain some cells from other lineages, and the relative rarity 
of NK cells in normal peripheral blood has been a significant 
impediment to studies requiring large numbers of  NK cells. 
To circumvent these difficulties, human NK clones have been 
Table 2.  Surface Antigens of Human Natural Killer Calls 
CD  % of NK Cells  Other Cell Types  Typical 
Cluster  Antigen  Expressing Ag.  Expressing  Ag  Antibodies 
CD2  SRBC receptor  -70-90  T cells, thymocytes  T1  1, Leu-5b. 9.6 
CD7  ~40  80-90  T cells, thymocytes  3A 1, Leu-9, G3-7 
CD8  MHC class I  ligand  30-40  CTL,  suppressor T cells  T8, Leu-2 
CDl  la  LFA- 1  >95  All leukocytes  2F12, MHM24 
CD1 lb  C3bi receptor (CR3)  80-90  Monocytes, PMN  Mol.OKM1. Leu-15 
CD1 IC  p150  -30-60  Macrophages, PMN  Leu-M5 
CD16  Fc y receptor 111  80-90  Macrophages, PMN  3G8, 873.1. Leu-1 1 
CD18  fl chain of CD 1  1  a-c  >95  All leukocytes  10F12, MHM23 
CD38  P45  -60-80  Activated T, plasma cells  T10, H87, Leu-17 
CD54  ICAM-1  -30-50  Many activated cells  RR1/1,OKT27 
CD56  NKH-1 (NCAM)  >95  NEC, few T cells  NKH-1, Leu-19 
CD57  HNK-1  50-60  T cell subset, NEC  L 186, Leu-7 
CD58  LFA-3  85-95  Many cells  TS2/9, ERIC5 
Abbreviations:  Ag. antigen; SRBC,  sheep erythrocyte; CTL, cytotoxic T lymphocyte; PMN, neutrophil; NEC, neuroendocrine cells. 
*Summarized from references 4.  5.  18,  29,  31,  36,  38,  78,  and 232.  For  some antigens,  variable results have been reported by different 
investigators. In particular, the percentages given for antigens expressed at low density (such as CD 1  1  b, CD1 IC,  and CD54) probably underestimate  the 
true values.36 
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derived  by  techniques  similar  to  those  used  to  clone  T 
 lymphocyte^.^"^^ NK clones were initially defined solely by 
their cytolytic activity against irrelevant allogeneic targets, 
and a number of cell lines originally described as NK clones 
have actually proved to be of T-cell  Some of these 
“NK-like” T-cell clones are probably derived from the rare 
peripheral  blood  T  cells  that  express  CD56  and  exhibit 
spontaneous non-MHC-restricted cytotoxi~ity.’~.~~  As with T 
cells in general, most of these CD56 + T cells express typical 
a//I T-cell receptors. Furthermore,  CTL clones with NK 
activity can arise from the small subset of  T cells that have 
y/6  T-cell   receptor^.^'.^^  Although  most  freshly  isolated 
peripheral blood y/6 T cells do not express CD56 or exhibit 
NK activity, the majority can  be  induced to kill without 
MHC  restriction  by  short-term  culture  in  IL-2  al0ne.4~ 
Although T-cell clones with NK activity are interesting in 
their  own  right,  the  term  NK  clone should  probably  be 
reserved for cell lines lacking CD3 and T-cell receptors; a 
germline configuration of TCR genes has been demonstrated 
for some NK clones as well.25  CD56 expression by clonal cell 
lines does not necessarily indicate NK cell lineage, because 
antigen-specific  T-cell clones can acquire CD56 after in vitro 
cuIture.48 
Prolonged propagation of  NK clones has  been  difficult, 
although selected clones have been grown for several years by 
frequent subcloning with irradiated feeder cells; these NK 
clones have demonstrated a stable surface antigen phenotype 
and cytolytic a~tivity.~,~’,~~  Clonal NK cell lines have proved 
invaluable for  studies of  NK cell antigen  expression, cy- 
tolytic  activity,  and  cytokine  production.  However,  such 
clones represent relatively activated NK effectors, and single 
clones do not reflect the known heterogeneity of  polyclonal 
NK cell   population^.^  Optimally, studies using  polyclonal 
NK cells should complement those performed on NK clones. 
ORIGIN AND DIFFERENTIATION OF  NK CELLS 
Considerable data indicate that NK cells are derived from 
bone marrow precursors. Marrow grafts can reconstitute NK 
cells in lethally irradiated laboratory animals; the regenerat- 
ing NK cells have  been  shown to be of  donor origin.233-235 
Engraftment  of  NK cells  has  also  been  demonstrated  in 
patients undergoing allogeneic marrow transplantation  for 
hematologic malignancie~.’~~‘’~~  Furthermore,  lymphocytes 
with  an  NK  surface  phenotype and  typical  NK  activity 
can  be  generated  in  vitro  from  bone  marrow  precursor 
ce11s.’10~236.237  Several cytokines appear to regulate the differ- 
entiation of  mature NK cells in such in vitro  culture^."^^^^^ 
The precise relationship of  NK cells to other hematopoietic 
cell types remains controversial. Detailed characterization of 
leukocyte  differentiation  antigens  has  not  permitted  an 
unambiguous attribution of lineage because NK cells share 
surface antigens with both T cells and myeloid cells (Tables 1 
and 2). Marrow grafting experiments in mice have shown 
that NK cell precursors can be  transplanted  from mutant 
strains  lacking  T-  and  B-cell  progenitors235  or  myeloid 
progenitors.234  Thus murine NK cells probably constitute a 
third lymphoid lineage comparable to T cells and B cells. 
It is not certain whether NK cells differentiate entirely in 
the bone marrow, but most data suggest that thymic process- 
ing is not  required.233-237.250  Aft er being released from the 
marrow, most  NK cells appear  to circulate in  peripheral 
blood or migrate to the spleen; very few are detectable in the 
thymus  or  lymph  nodes  of  healthy   person^.^^'^^^^  Factors 
influencing NK cell migration and  localization are poorly 
understood. Furthermore, the lifespan of  NK cells has not 
been well-characterized; lifespans ranging from a few days to 
several months have been reported for laboratory ani mal^.^^*^^ 
Like other lymphocytes, but unlike fully differentiated my- 
eloid cells, at least some mature peripheral blood NK cells 
retain proliferative ~apability.’~~*’~~ 
CYTOLYTIC ACTIVITY  OF  NK  CELLS 
For several years NK cells could be defined only function- 
ally as lymphocytes capable of  mediating the spontaneous 
killing of  target cells. Such NK activity is characterized by 
several features that clearly differentiate it from the typical 
cytolytic activity of T cells: 1) it occurs within hours of target 
cell exposure without deliberate prior immunization; 2) it 
does not require target cell expression of  appropriate self- 
MHC antigens; 3) it does not appear to involve a clonally 
distributed spe~ificity.~*’~’~  NK activity is usually determined 
by  measuring the release of  radiolabeled chromium  from 
target cells that have been exposed to effector cells.50  Tumor 
cell lines such as K562 (derived from a patient with chronic 
myelogenous leukemia in blast phase), Molt-4 (derived from 
a  patient  with  acute  lymphoblastic leukemia),  or  Daudi 
(derived  from  a  patient  with  Burkitt’s  lymphoma)  are 
commonly used as targets in such assays; virus-infected cells 
or fresh tumor cells may also be  used.  Because it  is very 
sensitive to NK cytolysis and does not express MHC anti- 
gens, K562 is frequently the target cell of choice for standard 
NK activity assays.” Although cell lines are often described 
as “NK-sensitive” or “NK-resistant,” these should be consid- 
ered relative terms; sensitivity to NK killing represents a 
spectrum and varies depending on experimental conditions 
(presence of  stimuli, effector-to-target ratio, duration of  the 
assay, etc). 
Lack of  restriction by syngeneic MHC antigens is one of 
the  defining  characteristics  of  NK  cytotoxicity.  Indeed, 
sensitivity to NK killing appears to be inversely related to 
target cell expression of  MHC  glycoprotein^.^'  Mutant cell 
lines with  diminished surface  MHC expression are more 
sensitive to NK cytolysis than are their parental cell 
NK resistance can  be restored  by  transfection  of  normal 
MHC or /I2 microglobulin  gene^.^^.^^ Furthermore, “masking” 
of  target cell MHC antigens using MoAbs increases target 
cell susceptibility to NK  effector^.'^  It has been  suggested 
that MHC glycoproteins might  inhibit  the  recognition of 
other surface antigens by NK cells or could interact with NK 
surface  structures  that  transmit  a  negative  signal  for 
~ytolysis.~‘,~~ 
NK cells are capable of dual cytolytic activity; in addition 
to  spontaneous antibody-independent non-MHC-restricted 
cytotoxicity  (NK  activity),  they  can  mediate  antibody- 
dependent  cellular  cytotoxicity  (ADCC).5,56,57  In  ADCC, 
antibody-coated target cells are lysed by effector cells bear- 
ing Fc receptors for immunoglobulin; effector cells express- 
ing Fc receptors and capable of  ADCC include NK cells, 
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monocytes, and granulocytes. Because the “ADCC receptor” 
of NK cells is well-characterized, it will be considered first, 
followed by a discussion of the more elusive “NK receptor.” 
The  CD  16 
antigen (Fcy R  111) is a 50 to 70 Kd heavily glycosylated 
polypeptide  expressed  by  80% to  90% of  NK ~ells,~,~~*~~ 
essentially  all   neutrophil^,^^  some   eosinophil^,^^  a  small 
fraction of resting peripheral blood monocytes6’ and T cells,6’ 
and most  activated monocytes and tissue  macrophage^.^^.^^ 
CD16 binds the Fc region of human IgGl and IgG3 with low 
affinity (K, -  5 x  lo5  M-’); it does not bind IgG2 or IgG4 
dete~tably.~’.~~  Of interest, the CD16 present on granulocytes 
is biochemically and serologically distinct from that of NK 
~ells.~~,~~  CD16 is attached to the membrane of neutrophils 
via a phosphatidylinositol glycan moiety, whereas the CD  16 
of  NK cells is an integral transmembrane protein.63 These 
extremely homologous molecules are encoded by two sepa- 
rate but tightly linked genes on human chromosome  l.58,63 
The longer  cytoplasmic domain  of  NK cell  CD16  may 
participate  in  NK cell  triggering  during ADCC.64 Such 
triggering may also involve the {chain, a 32 Kd homodimer 
implicated  in  activation  through  the  T-cell  receptor.65966 
Although  they  express  neither  CD3 nor  T-cell  receptors, 
most NK  cells do express the “TCR” {  chain.67  The {chain 
has been shown to associate with CD16 on NK  ~ells~~*~~  and 
activation through CD16 results in tyrosine phosphorylation 
of {.70  Crosslinking of NK  surface CD16 induces a rapid rise 
in cytosolic free calcium ion concentration and the produc- 
tion of  inositol- 1,4,5 trisph~sphate,”,~~  both  important bio- 
chemical messengers during lymphocyte activation. Trigger- 
ing  of  NK cells  through  CD16 ultimately  results  in  the 
expression  of  activation  antigen^^^.^^  and the secretion  of 
cyt~kines.~*.~~  CD16 appears to be solely responsible for the 
ADCC of NK cells, because  CD16 blocking with immune 
complexes  or  CD16 modulation with  MoAbs  or  phorbol 
esters abrogate this cytolytic a~tivity.’~.~~ 
Spontaneous  non-MHC-restricted  cytotoxicity  and  the 
NK receptor.  Activation  through  CD16 can thus trigger 
NK cells to kill antibody-coated  targets. Despite intensive 
investigation, the receptors mediating antibody-independent 
NK activity remain elusive.  Conjugate formation between 
NK cells and target cells is necessary but not sufficient for 
NK activity; it is largely mediated by the binding of NK  cell 
surface LFA-1 (CDl la/CD18) and CD2 to their target cell 
ligands,  ICAM-1  (CD54)  and  LFA-3  (CD58)  respec- 
ti~ely.~.~~.~’  ICAM-1 on NK cells may also be involved in 
adhesion  to  target  ~ells.~~,~~  After  conjugate  formation, 
further recognition  events have  been  postulated  to trigger 
NK cell lytic activity,  analogous to the triggering of  CTL 
through the clonotypic T-cell receptor. Nonetheless, neither 
specific  “NK receptors”  nor  cognate target  cell  receptor 
ligands have been identified. Several MoAbs initially thought 
to recognize NK receptors based on their ability to inhibit 
NK activity  have  been  found  to react  with  cell  adhesion 
molecules; presumably they interfere with NK cytolysis by 
inhibiting initial conjugate  formation  rather  than by  the 
triggering of lysis.4 However, CD2 can mediate both conju- 
gate formation and the cytolytic activation of NK   cell^.^^^^' 
Activation of T cells through CD2 involves phosphorylation 
of  the TCR { chain,8’ and { may also participate  in  the 
Antibody-dependent  cellular  cytotoxicity. 
triggering of NK  cells through CD2 or other NK  cell surface 
structures. Indeed, the NK  {chain is associated with proteins 
other than CD16, and these are being evaluated as possible 
NK   receptor^.^^.^^ 
Other cell adhesion molecules might also subserve receptor- 
like  functions  under  certain  circumstances.23g We  have 
recently  characterized  the expression  of  several  adhesion 
molecules by NK  cells and have demonstrated that NK cell 
target specificity can be  regulated by  changes in adhesion 
molecule expre~sion.~~  Others have shown that laminin-like 
molecules  are expressed  by  both  human  and murine  NK 
~ells.~*~~~  Heteroantisera or MoAbs to these molecules inhibit 
the cytolytic  activity  of  both  resting and stimulated NK 
effectors, possibly by inhibiting both adhesions2 and trigger- 
ing.83 One  group  has  developed  MoAbs  that  recognize 
surface structures common to human, rat, and catfish NK 
effectorsg4 and  also  MoAbs  to  target  ligands  present  on 
human and murine NK-sensitive  cell  lines as well  as fish 
 parasite^.^^,'^ Because all MoAbs that blocked NK  cytolytic 
activity  did  so  by  inhibiting  conjugate  formation,  these 
MoAbs would appear to define adhesion molecules involved 
in NK cytotoxicity that have been highly conserved during 
evolution. However, it remains to be demonstrated that any 
known NK surface structure can trigger NK activity after 
binding its physiologic target cell ligand. 
Although the 
receptors for NK activity and ADCC are probably distinct, 
these two cytolytic pathways would appear to involve com- 
mon terminal effector mechani~ms.8~.’~  Commensurate with 
their  LGL morphology,  resting NK cells have  preformed 
cytolytic granules that can be discharged immediately after 
exposure  to sensitive target  cells.’  Granule  exocytosis  re- 
leases  perforins,  serine esterases,  and chondroitin  sulfate 
proteoglycansgs~s9  into areas bounded by the close apposition 
of effector cell and target cell plasma membra ne^.'^.^' Perfor- 
ins  (also called  cytolysins  or  pore-forming  proteins)  are 
inserted into the target cell membrane as monomers, subse- 
quently  polymerizing  to  form  cylindrical transmembrane 
pores that permit osmotic lysis of the target ~e11.~~~~’  Mem- 
brane lesions produced by NK cells and CTL appear to be 
identical, and closely resemble those produced by the mem- 
brane attack complex of ~omplement.~’~~’  Perforin-mediated 
membrane damage is not the sole mechanism of NK cytoly- 
sis, however. NK cells also secrete soluble toxins, collectively 
called  NK cell  cytotoxic  factors  or  NKCF’  (Table  3). 
Tumor necrosis factor (TNF-a) is a major mediator of the 
soluble lytic activity  of  NK cells,  but  other  proteins  are 
probably involved as we11.g7*90.99  TNF-a appears to activate a 
target cell endonuclease that degrades genomic DNA into 
180 to  200  base  pair  fragments.’”’’ This  process,  called 
apoptosis  or  programmed  cell  death,  involves  the  active 
participation of  TNF-sensitive target cells,  unlike  the os- 
motic lysis caused by perforins  or complement.”  CTL can 
also  induce  such  target  cell  “suicide,”  possibly  through 
secretion of TNF-a or TNF-@.90s’0’ 
The  function of the serine esterases and sulfated proteogly- 
cans found in the granules of NK cells remains unclear. The 
serine esterases could be involved in the activation of perfor- 
ins  or  other  lytic effector   molecule^,^^*^^  and  at least  one 
esterase (granzyme A) has been  implicated in  target cell 
Terminal cytolytic effector mechanisms. 
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Table 3.  Cytokine Production by NK Cells 
Resting  Activated 
Cvtokine  NK  Cells  NK Cells  References 
IL- 1 
IL-2 
IL-3 
GM-CSF 
G-CSF 
M-CSF 
IFN-a or j3 
IFNr 
TNF-a 
TN  F-j3 
0 
0 
0 
?+ 
0 
0 
0 
0 
0 
0 
0. 
0 
+ 
+ 
0 
+ 
?+ 
+ 
+ 
+ 
92,93,247,248 
5, 94 
92 
92,95 
92 
92 
96,97 
72, 73, 92, 96 
72. 73. 92, 96, 98 
96 
Various stimuli were used to activate NK cells in vitro, including IL-2, 
antiCD  16 MoAb, combinations of calcium ionophore and phorbol ester, 
and exposure to target cells.  Negative results do not necessarily prove 
that NK cells cannot produce a given cytokine, since other stimuli might 
be able to induce production. 
Abbreviations:  IL,  interleukin:  CSF,  colony  stimulating  factor  (G, 
granulocyte  and  M, monocyte):  IFN,  interferon: TNF,  tumor  necrosis 
factor: 0, none detected; +, detected: ?+,  conflicting results reported. 
*The preponderance of  the data suggests that CD3 + LGL.  but not 
CD3 -  NK cells, can produce IL-1. 
DNA fragmentation  induced by  CTL.'"  It has been  sug- 
gested that the proteoglycans bind other granular compo- 
nents or  help protect  the  effector cell from its own  lytic 
fact0rs.8~  Further work is needed to test these hypotheses. 
REGULATION OF  NK  CELLS: THE  CENTRAL ROLE  OF  IL-2 
Several  cytokines have  been  shown to  affect  NK  cell 
proliferation or cytolytic activity (Table 4). Of  these, the 
interferons (IFN) and IL-2 have been the most extensively 
studied. The interferons were initially identified as proteins, 
secreted by virus-infected cells, that inhibited viral replica- 
ti~n.'~~  The biochemistry, serology, and  genetics of  these 
important immunomodulatory cytokines have subsequently 
been  well-characterized.'z4~'2s  Interferons a  and /3  comprise 
at least 15 related proteins that appear to interact with the 
same cell surface receptor; IFN-7 is a structurally distinct 
protein that binds to a different recept~r.'~~''*~  All three types 
of interferon can augment the cytolytic activity of NK cells, 
although the potency of this effect differs among the various 
molecular species that have been tested.'16,128  In general, the 
a  and /3 interferons stimulate NK activity to a greater degree 
than does IFN-7. Enhanced NK cytolytic activity is evident 
within 4  to 6 hours of  IFN exposure, requires RNA but not 
DNA  synthesis,  and  is  tran~ient."~.'~~.''~  Although  early 
studies suggested that IFN could augment only the killing of 
targets already sensitive to NK activity,"4*11s*130  subsequent 
work demonstrated that IFN could induce the lysis of  cells 
relatively resistant to unstimulated NK  cell^.'^^^'''*''^ Interfer- 
ons  by  themselves do  not  cause  NK  cells to proliferate; 
indeed they appear to inhibit the NK proliferation induced 
by IL-2."4-"6 On the other hand, IFN and IL-2 can synergis- 
tically augment NK cytoto~icity.'~~~''~~''~ 
Shortly after IL-2 was isolated and  it 
was shown that peripheral blood NK cells could proliferate 
and exhibit enhanced cytolytic activity in response to IL-2 
al~ne.'~~-'~~  The past  few  years  have  seen  a  remarkable 
increase in our understanding of  the IL-2 receptor and the 
role of  IL-2 in the biology of  NK cells. The IL-2 receptor is 
now  known to consist of  at least two  The low 
affinity  receptor  or  CD25  (Tac  antigen,  IL-2Rp55)  is  a 
polypeptide of  -55  Kd that binds IL-2 with an equilibrium 
dissociation constant (Kd) of  1.7 x  mol/L, whereas the 
intermediate affinity receptor (IL-2Rp75) has a M, of  70 to 
75 Kd  and  a  Kd  of  1.0  x  mol/L.  IL-2Rp75 has a 
relatively large cytoplasmic tail and can transduce functional 
signals in the absence of the p55 chain; IL-2Rp55 has a short 
cytoplasmic segment and has not  been  shown to transmit 
signals al~ne.'~~.'~~  Expressed together on the cell surface, the 
p55 and p75 chains can associate to form a heterodimer with 
high affinity for soluble IL-2 (Kd, 2.6 x lo-'' mol/L). 
The majority of  peripheral blood NK cells constitutively 
express only  the  intermediate  affinity  IL-2 receptor,  and 
relatively  high  concentrations  of  IL-2  (-1  nmol/L)  are 
required  to  stimulate these   lymphocyte^.'^.'^^.'^^  However, 
the small subset of  CD56"b"gh'"  CD16-  NK cells constitu- 
tively  expresses high  affinity IL-2 receptors as well  as an 
excess of free IL-2Rp75  chain^.^^.^^ These NK cells respond 
Table 4.  Effect of Cytokines on Human NK Cell Function 
Resting NK Cells  IL-2-activated NK Cells 
Cytokine  Cytotoxicity  Proliferation  Cytotoxicity  Proliferation  References 
IL- 1 
IL-2 
IL-3 
IL-4 
IL-7 
IFN-aIj3 
IFN? 
TNF-a 
NKSF 
PDGF 
t 
t 
t 
t 
t 
t 
t 
1 
0 
0 
0 
0 
0 
0 
0 
0 
t 
__ 
-_ 
__ 
t 
tlt 
t 
t 
t 
0. 
0 
__ 
0 
t  103-106 
107, 108 
110 
111,112 
249 
114-1 16 
114-1 18 
106, 119, 120 
121 
122 
Abbreviations: PDGF, platelet-derived growth factor: NKSF, NK cell stimulatoryfactor: t, augments: 1, inhibits, 0, no effect ti,  variable effect: -  -, 
effect not reported. 
*IL-3  has little effect on peripheral blood NK cells, but can inhibit IL-2  mediated generation of NK activity from bone marrow depleted of mature NK 
effectors.'" 
tWhen human P8L are preincubated with IL-4  or  incubated simultaneously with IL-2 and IL-4,  induction of LAK  activity by IL-2  is inhibited."'.''2 
When IL-4 is added to human P8L already cultured in IL-2, LAK  activity is augmented."'  By contrast, IL-4  alone can induce LAK activity by murine 
lymphocytes. '  l3 
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to  10- to-100-fold  lower  IL-2 doses  than those  needed  to 
stimulate CD56“d”” CD16+ NK  cells. NK  cells demonstrate 
enhanced  target  cell  killing  within  4  to 6 hours  of  IL-2 
exposure,  but optimal stimulation of  cytolytic  activity  re- 
quires the presence of IL-2 for at  least 18 to 24 ho~r~.~~,~~~,~~~,~~~ 
Antibodies  to  the IL-2Rp55  chain  that disrupt  the high 
affinity IL-2 receptor’34  do not inhibit the augmentation of 
NK cytotoxicity by IL-2; thus the activation of NK  cytolytic 
activity appears to be mediated by the intermediate affinity 
By  contrast,  NK cell  proliferation  may 
require expression of the high affinity IL-2 receptor. Contin- 
uous exposure to IL-2 for 3 to 4 days is generally required to 
induce NK  cell proliferati~n,~~~.’~~  and this proliferation can 
be markedly inhibited by anti-IL-2R~55.’~’,’~~  Furthermore, 
IL-2 has been  shown  to induce NK cell  synthesis of  IL- 
2R~55.’-’’.’~~  Thus it is possible that NK  cell proliferation in 
response to IL-2 occurs predominantly through high affinity 
IL-2 receptors formed by  the association of  newly synthe- 
sized  IL-2Rp55 with  the IL-2Rp75 that is  constitutively 
expressed by NK  cells. Alternatively, additional factors may 
be required  to induce proliferation  of  NK cells expressing 
only IL-2Rp75. 
The intracellular biochemical events induced by binding of 
IL-2 to its cell surface receptor are  essentially unknown. IL-2 
stimulation of  T and  B  lymphocytes  does  not  appear to 
involve the calcium-dependent phosphoinositol  and protein 
kinase C path~ays’~~*I~~  or the participation of cyclic AMP  or 
GMP as second messengers.138  After  IL-2 exposure, acti- 
vated T cells exhibit rapid phosphorylation of several cellular 
proteins, including tyrosine phosphorylation of the IL-2Rp75 
chain.’39  However, it is not clear that such phosphorylation 
accompanies signal  transduction through the intermediate 
affinity  receptor  expressed  by  freshly  isolated  NK cells. 
Synthesis of  c-myb mRNA can  be  detected in  NK cells 
within two hours of IL-2 exp~sure.~~~,~~~  Although the prod- 
uct of this cellular protooncogene appears to be involved in 
IL-2-induced lymphocyte pr~liferation,’~~  its possible role in 
regulating NK cell  cytolytic  function  has yet  to be fully 
defined.239 
The effects  of  IL-2 that ultimately produce  augmented 
cytolytic  activity  are  also  poorly  understood.  Initial 
rep~rts’~’*l~~  that IL-2 exerted its effects  on  NK cells  by 
stimulating  autocrine  secretion  of  IFN-7  have  proved 
errone~us.’~~.’~~  IL-2 induces  increased  expression of  some 
NK  cell surface adhesion molecules, apparently mediating in 
part the induction of cytotoxicity for NK-resistant targets.78 
An increase in  the number and size of  NK cell  cytolytic 
granules  has  also  been  demonstrated  following  IL-2 
a~tivati0n.l~~  Furthermore, IL-2 stimulates NK cell expres- 
sion of mRNA for some serine protea~es.’~’  Because all of 
these changes require several days of  IL-2 exposure, they 
cannot  account  for  the earliest  increase  in  NK cytolytic 
activity. Elucidation of the mechanisms of NK  cell activation 
by IL-2 remains an area of active investigation. 
ROLE  OF  NK CELLS IN NORMAL PHYSIOLOGY 
Resistance to microbial pathogens.  Of the various phys- 
iologic functions ascribed to NK cells, antiviral activity has 
perhaps  been  documented  most  persuasively.  Numerous 
studies have demonstrated that NK  cells can selectively lyse 
virus-infected target cells while sparing uninfected ~ells.’~.~~~ 
IFN secreted  by accessory cells or NK cells themselves in 
response to viral infection potentiates the cytolytic activity of 
NK cells, whereas IFN has been  shown to protect normal 
cells preferentially from NK  ~ytolysis.~~*~~~  IFN activity thus 
partially  accounts  for  the efficient  and  selective  lysis  of 
virally infected cells by NK effectors.  However, IFN is not 
solely  responsible,  or  even  absolutely  necessary,  for  NK 
killing of virus-infected  ce11s.97,’46,’47  The expression of viral 
antigens or other surface structures by infected cells appears 
to render them more sensitive to NK ~ytolysis.~~,’~~-~~~ 
Mammalian cells infected by many different viruses (in- 
cluding  herpes,  vaccinia,  measles,  mumps,  and influenza 
viruses) can be lysed in vitro by  NK cells.97 However, the 
bulk of the data supporting a role for NK  cells in resistance to 
viral infection in vivo are from studies of murine herpesvirus 
 infection^.^^.*^^  Strains of  mice  with  relatively  low  NK 
activity are more susceptible to herpes simplex and cytomeg- 
alovirus infections. Adoptive transfer of marrow from virus- 
resistant strains to lethally irradiated virus-sensitive  mice 
confers resistance to viral infections, whereas treatment with 
reagents  that  inhibit  NK activity  abrogates  such  resis- 
tance.97.23 1,240  Furthermore, infusions  of  anti-asialo  GM  1, 
which inhibit NK function in vivo, increase the severity of 
influenza pneumonia in mice or hamsters.14’ Murine hepati- 
tis virus infections are  also more severe in mice treated in vivo 
with anti-asialo GM1 
The extreme rarity of isolated human NK  cell deficiency 
has made it difficult to demonstrate the importance of NK 
antiviral activity  in  man.  Patients with  Chediak-Higashi 
syndrome or leukocyte adhesion deficiency disease demon- 
strate impaired  NK function,  but  their  clinical  course is 
generally  determined by  the concomitant granulocyte ab- 
n~rmality.’~~.’~~  Biron  et alls2 have described  the complete 
and apparently isolated deficiency of NK  cells in a teenage 
girl. This patient experienced a series of life-threatening viral 
infections,  including  primary  disseminated  varicella,  pri- 
mary cytomegalovirus pneumonia, and severe primary cuta- 
neous  herpes  simplex  infection.  The PBL  of  this patient 
expressed neither CD56 nor CD16 and demonstrated no NK 
activity even after stimulation with IL-2 or IFN-a. Limited 
in vitro testing disclosed normal neutrophil, T cell, and B cell 
function.  With antiviral therapy and supportive  care, the 
patient eventually recovered  from each infection; a normal 
specific T-cell response and a rise in specific antibody titers 
were documented during her convalescence from the vari- 
cella infection. This case provides  the best direct evidence 
that NK cells play a crucial role in human defenses against 
herpesvirus infection. Presumably, NK effectors hinder viral 
dissemination and limit the total burden of pathogen during 
the early phases of  infection,240  whereas the more delayed, 
antigen-specific humoral and T-cell immune responses medi- 
ate ultimate control of the virus. 
NK cells  can  kill  other  infectious  pathogens  in  vitro, 
including both gram-positive and gram-negative bacteria,I6 
the fungus Cryptococcus neoforman~,’~~  and the protozoa 
Toxoplasma g~ndii”~  and Trypanosoma cruzi.’” NK  bacte- 
ricidal  activity  has been  shown to involve the secretion  of 
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soluble factors,I6 whereas direct cell-mediated  lysis appears 
to underlie the killing of fungi and protozoa. Activated NK 
cells have also been reported to lyse preferentially monocytes 
infected  by  intracellular  ba~teria.'~'.~~~  The  relevance  of 
these findings to normal physiology  in vivo remains to be 
determined. 
The phenomenon  of  hy- 
brid resistance in mice first suggested that NK  cells might be 
involved  in  the  regulation  of  hematop~iesis.'~~  Lethally 
irradiated F, hybrid  mice were observed to reject parental 
hematopoietic grafts even though other parental grafts were 
tolerated. This hybrid resistance is genetically distinct from 
classical  allogeneic  immune responses  associated  with  the 
MHC complex. NK  cells were subsequently shown to be the 
predominant  effector  cells  responsible  for  hybrid  resis- 
tan~e."~.'~~  Some data suggest that other effector cells also 
participate in this phen0men0n.l~~ 
The effects of NK cells on human hematopoiesis in vitro 
have  been  studied by  several  investigators.  Typically,  he- 
matopoietic progenitor  assays have  been  performed  using 
normal  bone  marrow  or  peripheral  blood  that has  been 
exposed to NK  effectors or their supernatants. The data are 
somewhat  confusing;  both  stimulation  and  inhibition  of 
various colony forming units (CFU) by NK cells have been 
described. Partially purified  NK cells have been  shown to 
promote the erythroid burst-forming unit (BFU-E) activity 
of autologous peripheral blood.158  Furthermore, supernatants 
from highly purified NK  cells (-80%  to 95% pure) cultured 
in medium alone exhibit colony-stimulating activity for early 
myeloid progenitors from allogeneic peripheral blood or bone 
Activation  of  NK cells with IL-2 or IFN-y does 
not  enhance the colony-stimulating  activity, whereas this 
activity  is  diminished  but  not  abolished  by  neutralizing 
MoAbs to GM-CSF. The supernatants of similar NK cell 
preparations activated by exposure to an NK-sensitive  cell 
line, on the other hand, exhibit both colony-stimulating  and 
colony-inhibiting  activity;  the latter  was  shown to be due 
almost entirely to the presence of TNF.95  Degliantoni et 
have also described the colony-inhibiting activity of activated 
NK cells; the supernatants of CD16+ PBL stimulated with 
allogeneic bone marrow mononuclear cells or NK-sensitive 
target cells contained such inhibitory activity. TNF  appeared 
to  mediate  both  the  colony-inhibiting  activity  and  NK 
soluble cytotoxic activity in these supernatants. The ability of 
NK cells to produce cytokines was studied more rigorously 
by  Cuturi et  Polyclonal  NK cells were  expanded in 
culture by exposure to irradiated B-lymphoblastoid cells and 
then enriched to z 98% purity by negative selection. North- 
ern blot analysis of total cytoplasmic RNA failed to detect 
any constitutive expression of  GM-CSF, G-CSF, M-CSF, 
IL-1,  or IL-3 by these highly  purified  NK cells. However, 
NK cells could be induced to express mRNA for GM-CSF, 
M-CSF, or IL-3 using various stimuli (Table 3). NK cells 
stimulated  with  IL-2 and anti-CD16 MoAbs also secrete 
soluble inhibitory factors, including IFN-y and TNF.72.73 
Contamination of the purified NK cell fractions by small 
numbers of  non-NK effectors is a concern in these studies. 
Clonal populations of NK  cells have the obvious advantage of 
being free of all other cell types. Such NK  clones were found 
Regulation of  hematopoiesis. 
to  inhibit  the generation  of  CFU-Mix  (CFU for  mixed 
granulocyte, erthrocyte, monocyte, and megakaryocyte, colo- 
nies [CFU-GEMM]), CFU-GM, BFU-E, and CFU-E from 
allogeneic bone marrow; a period of close contact between 
the NK cells  and the marrow  cells  was  required  for the 
effect.'60 Different NK clones inhibited the different CFU 
variably, but in a clonally stable manner. Supernatants  from 
NK clones stimulated by  normal marrow cells or an NK- 
sensitive target cell line could also inhibit CFU formation, 
and this soluble inhibitory activity appeared to be due in part 
to IFN-y.  However, Niemeyer et all6' could demonstrate no 
inhibitory effect on marrow CFU-Mix, CFU-GM, CFU-G, 
CFU-M, or  BFU-E by highly  purified  polyclonal CD16+ 
autologous PBL. Differences in the activation states of  the 
NK  effectors might account in part for this discrepancy; NK 
clones are  continuously stimulated by the  conditions required 
for their propagation. 
Despite apparent contradictions in the results summarized 
above, it is  clear that NK cells  can affect  the growth of 
normal  human  hematopoietic progenitors in  vitro.  Under 
different  experimental  conditions,  NK cells  can  secrete 
soluble factors with either stimulatory or inhibitory activity 
(Table  3). The preponderance  of  the data suggests that 
activation of NK  cells is required for either activity; contact 
with early myeloid progenitor cells seems to be an adequate 
stimulus. Although NK  cells could also regulate hematopoie- 
sis  by  direct  lysis  of  myeloid  progenitor  cells,  there  is 
currently little evidence that this is important for the effects 
described. 
The theory of immune 
surveillance postulates that immune effectors can recognize 
and destroy spontaneously  arising malignant  tumor  cells. 
Early investigations designed to test this hypothesis focused 
on  cytotoxic  T  lymphocytes;  such  studies  were  largely 
disappointing and evoked some skepticism over the validity 
of  this theory.I6* However,  considerable experimental  evi- 
dence  suggests that  NK cells,  rather than T cells,  may 
mediate  the destruction of  autologous tumors.  Studies in 
mice revealed a direct correlation between the level of NK 
activity and resistance to  transplanted syngeneic  tumor^.'^'.'^^ 
Immunosuppressive  doses  of  cyclophosphamide render ro- 
dents more susceptible to injected malignant cells, and this 
sensitivity can be reversed by the adoptive transfer of either 
NK clones'65 or polyclonal lymphocytes highly enriched for 
NK  activity.'66  Neither polyclonal T cells166  nor CTL  clones,'65 
on the other hand, confer tumor resistance under identical 
conditions.  Furthermore, unfractionated  syngeneic spleno- 
cytes have been shown to mediate resistance to pulmonary 
metastases in cyclophosphamide-treated mice, whereas simi- 
lar splenocytes  depleted of  NK cells  did not  exhibit  this 
activity.'67 
It has been shown that NK  effectors can inhibit malignant 
tumor growth in vivo under experimental conditions.  It has 
been much more difficult to demonstrate that NK  cells are 
involved in immune surveillance against spontaneously aris- 
ing autologous tumors in man. Indirect supportive evidence 
comes  from  studies  of  patients  with  deficient  NK cell 
function. Patients with  the Chediak-Higashi  or  X-linked 
lymphoproliferative syndromes demonstrate abnormally low 
Elimination of  neoplastic cells. 
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NK  activity but relatively normal T-cell and B-cell function. 
These  patients  are particularly  susceptible  to  malignant 
lymphoproliferative  disorders,  possibly  as a result  of  their 
NK defi~iency.'~'.'~'.'~~  However,  this  susceptibility  could 
also reflect inadequate NK  antiviral activity with subsequent 
EBV-induced  lymphoproliferati~n.~~~  Deficient NK activity 
has also been  found  in  the members of  families  with  an 
apparent genetic predisposition to melanoma or other can- 
cers.  170,171 Numerous retrospective studies have documented 
subnormal NK cell function in  patients with  a variety of 
malignant t~m~r~.~~~*~~~~~~~  The degree of  NK impairment 
seems to correlate with disease status, being most marked in 
patients with advanced cancers. Depressed NK  activity could 
be an obvious consequence of the untreated or uncontrolled 
malignancy, rather than an antecedent state predisposing 
these patients to cancer. This issue can be addressed ade- 
quately only by a prospective, longitudinal study comparing 
the incidence  of  cancer in persons with high NK function 
with  that in otherwise  normal persons exhibiting  low NK 
activity. Such a study is unlikely to be undertaken because of 
practical considerations. 
Participation in  the  graft-versus-leukemia  efect  after 
bone marrow transplantation.  Bone marrow transplanta- 
tion  (BMT) provides curative treatment for some patients 
with  hematologic  malignancies.  BMT permits  the use of 
chemotherapy and radiotherapy in doses that would be lethal 
without  marrow  grafting,  and  the  high-dose  preparative 
regimens undoubtedly contribute to the antitumor efficacy of 
BMT. Nonetheless, substantial data suggest  that immune 
effector  cells  may  also  be  important  for  the control  of 
hematologic malignancies after BMT. Retrospective analy- 
ses  of  relapse  rates  after  transplantation  have  provided 
indirect  evidence  for  this  "graft-versus-leukemia"  (GVL) 
effect.  Despite receiving  similar preparative regimens,  pa- 
tients with acute or chronic leukemias who receive marrow 
grafts from identical twins  relapse much more frequently 
than patients with nonidentical sibling  donor^.^^^,'^^ Further- 
more,  patients  undergoing  allogeneic  BMT who  have  no 
graft-versus-host  disease (GVHD) relapse more often than 
patients with GVHD; relapse rates are inversely related to 
the severity of GVHD.174-176  Finally, depletion of T cells from 
bone marrow allografts can prevent GVHD  but has also been 
associated with a higher risk of relapse in several serie~.'~~,'~~ 
Because  mature alloreactive T  cells  mediate  GVHD in 
humans, these data imply that T cells can exert an antileuke- 
mic effect after allogeneic BMT. However, a  clinical trial 
attempting to enhance this effect by deliberately promoting 
GVHD proved prohibitively toxic and did not demonstrate 
better leukemic contr01.I~~ 
Laboratory studies indicate that NK cells can also have 
GVL  activity.  Similar  to  their  effects  on  normal  early 
myeloid  progenitors,  NK cells  can  inhibit the growth of 
clonogenic  tumor  cells  from  patients  with  myeloid 
1e~kemias.I~'  Unstimulated NK cells can readily  lyse cul- 
tured  leukemic cells,  and  tumor  cell  lines  derived  from 
patients with lymphoid and myeloid leukemias are  prominent 
among the classic "NK-sensitive"  targets.179  Although fresh 
leukemic  blasts are generally resistant to NK cell killing, 
they  can  often  be  efficiently  lysed  by  activated  NK 
effectors.180s18'  Furthermore, lymphocyte clones derived from 
the peripheral blood of patients undergoing allogeneic BMT 
can mediate GVL activity.  In one study of a patient with 
acute lymphoblastic  leukemia  (ALL), all clones  with cy- 
tolytic activity against cryopreserved autologous  blasts ex- 
pressed CD56 but not CD3 and had other characteristics of 
NK cells; cytogenetic analysis confirmed that these NK  cells 
were of donor origin.Is2 Indeed, NK  cells have been shown to 
engraft quickly after BMT, and can represent the majority of 
PBL during the first few weeks po~ttransplant.''~~''~  These 
NK cells appear to be endogenously activated and demon- 
strate enhanced  cytolytic activity  when  freshly  isolated. 
Although these activated NK effectors are seen after either 
autologous or allogeneic BMT, they are not detected after 
intensive combination chemotherapy a10ne.l'~  Clinical appli- 
cations of the GVL activity of NK  cells are discussed below. 
NK CELL  MALIGNANCIES AND THE  GRANULAR 
LYMPHOCYTE  PROLIFERATIVE DISORDERS 
Human NK cell  malignancies  appear to be quite rare. 
Three children with ALL of probable NK cell lineage have 
been  de~cribed."~  The leukemic  blasts  of  these  children 
expressed CD2 and Fcy receptors but not CD3  and mediated 
spontaneous killing of K562 target cells. A case of NK cell 
ALL has also been reported in an  adult; the malignant blasts 
of this patient demonstrated a characteristic NK  cell pheno- 
type but no cytolytic activity."'  Three patients with clinically 
aggressive leukemia involving CD3 -  large granular lympho- 
cytes have been des~ribed.~~~.'~~  The malignant lymphocytes 
of these patients expressed CD16 or CD56 and mediated NK 
cytolytic activity. Germline configurations of T-cell receptor 
and  immunoglobulin  genes  were  demonstrated  in  two  of 
these cases,194  and  a  clonal  cytogenetic  abnormality  was 
evident  in  the  third.'89  It  should  be  noted  that  CD56 
expression by malignant cells does not necessarily indicate an 
NK cell origin. CD56 has been detected on tumor cells from 
the majority of patients with small cell lung carcinoma195  and 
myeloma,196  as well  as a subset  of  patients  with  myeloid 
leukemias." 
Chronic proliferative  disorders  of  granular lymphocytes 
are more frequently recognized than acute leukemias with 
NK cell characteristics; more than a hundred patients with 
the former have been described over the past 15 years.'90193 
These patients typically present with a granular lymphocyto- 
sis, and a  peripheral blood  absolute granular  lymphocyte 
count in excess of  2,OOO/uL  for at least 3 months with no 
obvious cause is generally required for the diagnosis.193  Most 
patients  also  demonstrate  lymphocytic  infiltration  of  the 
bone  marrow.  Splenomegaly  is  present  in  about half  and 
hepatomegaly in 20% to 30% of patients, but lymphadenopa- 
thy  and  skin  involvement  are distinctly  unusual.  Severe 
neutropenia is typical and recurrent bacterial infections may 
occur. Associated diseases, most commonly rheumatoid ar- 
thritis, hepatitis, or cancer, are present  in 25% to 50% of 
patients.  The  clinical  course  of  these  patients  is  often 
relatively benign and many never require specific therapy. A 
variety of names have been given to these disorders, including 
large granular lymphocyte  leukemia, LGL lymphocytosis, 
lymphoproliferative disease of granular lymphocytes, chronic 
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granular lymphoproliferative  disorders, chronic granulated 
T-lymphocytosis, and Ty-lymphoproliferative di~ease.'~'.'~~ 
Although early phenotypic studies and the characteristic 
LGL morphology suggested that chronic granular lymphocy- 
toses were indeed NK cell malignancies,  subsequent work 
has demonstrated that CD3  + cells account for the expanded 
lymphocyte  population  in  most  patients.  These  granular 
lymphocytes also  commonly express CD16  and CD57.191-'93.'97 
Clonal TCR a/@  or 7/13  gene rearrangements  are usually 
detected if assayed, although this has been done in relatively 
few cases.  191.192,198 Thus, monoclonal proliferation  of T cells 
appears to underlie the granular lymphocytosis in most of 
these patients. Although fewer than 2% of T cells normally 
express  CD16, a small subset of  CD16+  T cells can be 
detected by flow cytometry in the peripheral blood of some 
healthy  persons.61 These CD3  + CD16+  lymphocytes  ex- 
hibit  LGL morphology  and mediate ADCC but  not  NK 
activity; most  are both  CD4 and CD8 negative,  but some 
express  low  levels  of  CD8. These normal  T  cells closely 
resemble the malignant lymphocytes present in most cases of 
the granular  lymphoproliferative  disorders;  whether  they 
represent the normal counterpart of the latter is uncertain. 
Although the CD3+  phenotype is by far the most com- 
mon,  in  a  minority  (about  15% to  30%)  of  patients  the 
granular  lymphocytes  are CD3-  but  CD16+  and  thus 
appear  to  be  NK cells;  CD56 expression  has  not  been 
examined in most ~eries.'~'-'~~*'~~  Increased NK  activity has 
been  described in about 20% of  all patients with  granular 
lymphoproliferative  disorders, although this does not neces- 
sarily correlate with the CD3 -  CD16+ phenotype. Because 
the CD3-  cells do not demonstrate TCR gene rearrange- 
merits  192. I98 and chromosomal abnormalities are rarely found 
in these disorders, it has been difficult to assess the clonality 
of the CD3 -  granular lymphocytoses. The NK cell expan- 
sion in some of  these patients may be reactive rather than 
neoplastic. 
THERAPEUTIC APPLICATIONS OF  NK CELLS 
Activated NK cells and the cellular immunotherapy of 
cancer.  Experiments first performed  more than a decade 
ago revealed that PBL cultured for several days in IL-2 could 
destroy fresh autologous and allogeneic tumor cells without 
MHC restriction; these lymphokine-activated  killer (LAK) 
cells could also efficiently kill target cell lines resistant to lysis 
by unstimulated NK   cell^.'^'*'^^ Because bulk LAK cultures 
contain  a  heterogeneous  mixture  of  cells,  it was  initially 
uncertain which cells mediated LAK activity. Early studies 
suggested that a novel cell lineage distinct from T cells or NK 
cells was responsible for the LAK phenomenon.200  However, 
substantial data now indicate that activated NK  cells are the 
predominant LAK  effector^.^'^^^'^  Though CD56  + T cells, 
CDl  lb+ T cells, and y/6 T cells may also mediate MHC- 
unrestricted cytotoxicity after IL-2 stim~lation,2~.~~.~~-~~'  they 
appear to contribute relatively little to the cytolytic activity 
of standard LAK cultures. Animal studies demonstrated that 
infusions of LAK cells could result in resistance to metastasis 
as well as the regression of established t~mors.~'~-~'~  Based on 
these observations,  initial phase I clinical  trials were con- 
ducted at  the National Cancer Institute (NCI) to determine 
the potential therapeutic utility of LAK cells in h~mans.~'~,~'' 
These trials used high doses* of  IL-2 (-100,000  U/kg by 
intravenous (IV) bolus  injection  every  8 hours) combined 
with infusions of LAK cells generated in vitro. Ten of the first 
25 patients  so  treated  demonstrated objective  partial  re- 
sponses, and one patient with melanoma experienced  com- 
plete regression of all disease for greater than 10  month^.^" 
All patients  had  advanced cancers for which  no effective 
therapy had previously  been  available.  These encouraging 
results  prompted  further  clinical trials,  performed  at the 
NCI  and elsewhere, using high-dose IL-2 alone or in combi- 
nation with LAK cells. These studies confirmed the modest 
efficacy  of  IL-2/LAK  therapy;  objective  responses  were 
demonstrated  in  16% to  35%  of  patients  with  renal  cell 
carcinoma  and  19% to  21%  of  patients  with  malignant 
melanoma.208-2'0  A small number of durable complete remis- 
sions have  been  described.208-210  Limited  studies involving 
patients on these protocols have confirmed that activated NK 
cells, rather than T cells,  appear to be responsible for the 
LAK  activity  generated  in  vivo  by  the  high-dose  IL-2 
infusions as well as in the bulk in vitro cult~res.~'~*~'' 
Although  the IL-2/LAK  trials demonstrated that acti- 
vated  lymphocytes  can cause the regression  of  advanced 
cancers in humans, they have also documented substantial 
systemic toxicity.208-210  In attempts to improve the response 
rate and limit toxicity, many investigators have undertaken 
modifications  of  the original Rosenberg protocol.  Because 
standard LAK cultures contain large numbers of T cells that 
do not appear to be cytolytically active, adoptive immunother- 
apy using  highly  enriched NK effectors  has been  under- 
taken.243*244  Hercend  et  have administered  IL-2 and 
lymphokine-activated natural killer  (LANAK) cells to 12 
patients with metastatic renal cell cancer. In most cases more 
than 85% of  such LANAK cells were CD56+, whereas T 
cells accounted for fewer than 5% of cells infused. Compared 
with  unfractionated  LAK cells,  LANAK cells  exhibited 
approximately 100-fold greater killing of NK-resistant tar- 
gets  in  standard  cytotoxicity  assays.243 Objective  partial 
responses  were  seen  in  three  of  nine  evaluable  patients 
treated  with  IL-2  and  LANAK  cells.  Purification  and 
expansion of LANAK cells in vitro are, however, arduous 
procedures.243 Short-term  incubation  of  PBL  with  IL-2 
results  in  preferential  adherence  of  NK cells  to  plastic 
culture flasks, and adherent LAK (A-LAK) cells have much 
more potent cytolytic activity than do unfractionated LAK 
ce11s.229,244*245  The P  ittsburgh group has undertaken a phase 
1/11 clinical trial of  IL-2 and A-LAK cells in patients with 
melanoma and renal cell carcinoma.244 
Although preclinical and initial clinical studies suggested 
that neither high-dose  IL-2 alone nor LAK cell infusions 
alone had  significant  antitumor effect,206  subsequent work 
has shown  that treatment  with  high-dose  IL-2  results in 
*Throughout this review, doses of IL-2 are given in International 
Units, which are the same as those used by the Biological Response 
Modifiers Program at the NCI. When investigators have reported 
their  doses  in  "Cetus units," the  latter  have  been  converted  to 
International  Units  for  ease  of  comparison.  One  Cetus  unit  is 
approximately equivalent to 3 to 6 International Units. 
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overall objective response rates comparable with those ob- 
tained  with  combined  IL-2/LAK  therapy.208-212  A  large 
prospective randomized trial at  the NCI demonstrated more 
complete responses in patients receiving both IL-2 and LAK 
cells  compared  with  those  receiving  IL-2  alone,  but  no 
significant differences in overall responses or survival.212  It is 
presently  unclear whether infusions  of  LAK cells add any 
therapeutic benefit  over  high-dose  IL-2 alone.  IL-2 itself 
possesses  no  known  direct  antineoplastic  effect,  and  its 
efficacy  when  used  alone  probably  reflects  the killing  of 
tumor cells by NK  effectors expanded and activated in vivo. 
However, direct tumor cell lysis by activated NK cells may 
not be the only mechanism causing tumor regression. Other 
effector  cells  might  be  recruited  in  vivo,  and  cytokines 
released  by  several  cell types  in response to IL-2 may be 
important as well. Indeed, endogenous production of IFN-y 
and  TNF has  been  detected  in  patients  receiving  IL-2 
Several groups are using IL-2 alone in various doses and 
schedules to treat patients with advanced cancer. The Madi- 
son group has administered IL-2 by continuous infusion or 
IV  bolus  at doses  of  1.0  or  3.0  x  lo6 U/m2/day  for  4 
consecutive days on each of 4 consecutive  week^.^'^.^'^ Toxic- 
ity was  generally mild; patients  were  treated on  medical 
oncology  wards  and  no  patient  required  transfer  to  an 
intensive  care unit.  Three of  seventeen  patients  with  ad- 
vanced  renal  cell  cancer  demonstrated  objective  partial 
responses;  no  responses  were  seen  in  six  patients  with 
The Loyola  group has treated patients with 
advanced melanoma or colon cancer using repetitive once or 
twice weekly infusions of  IL-2 at doses from 1.0 x  lo3  to 
3.0 x  lo7  U/m2; doses up to 1.0 x  lo6  U/m2/day were very 
well tolerated.216  Objective partial responses were seen in two 
of six patients with melanoma. Both the Madison and Loyola 
investigators reported very similar changes in the peripheral 
blood  of  patients  receiving  this  "moderate  dose"  IL-2 
therapy.211*215-217,2'8  IL-2 induced  a  prominent  eosinophilia 
and an initial lymphopenia followed by a rebound lymphocy- 
tosis. Dramatic increases in peripheral blood NK cells were 
seen, with a  preferential expansion  of  cells expressing the 
CD56"bright"  CD16 - phen~type.~'~.~'~  PBL  from these  pa- 
tients exhibited enhanced killing of NK-sensitive targets and 
could  lyse  NK-resistant  targets  without  any  in  vitro 
acti~ation.~'~,~'~  Sorting and complement  lysis experiments 
confirmed that virtually all of this LAK activity was medi- 
ated by NK cells and not by T cells.2".2'8 Furthermore, the 
CD~  6"bright"  CD16-  NK cells appeared to be more potent 
LAK effectors than the CD56"dim"  CD16+ 
Outpatient administration of  biologically  active doses of 
IL-2 has also been shown to be feasible. Ambulatory patients 
have tolerated several weeks of  IV bolus  or intramuscular 
IL-2 given  5 days weekly  in doses  from  1.0 to 3.6  x  lo6 
U/m2/day.219-22'  In  one study, immunomodulatory effects 
similar to those described by the Loyola and Madison groups 
were reported.219  In an ongoing phase I trial at the Dana- 
Farber  Cancer  Institute,  patients  with  advanced  cancer 
receive  continuous  intravenous  infusions  of  IL-2  for  90 
consecutive  days entirely on  an outpatient  basis.  IL-2 so 
given has been well tolerated in doses as high as 6.0  x  lo5 
U/m2/day.  Even  at this  relatively  low  total  daily  dose, 
patients have demonstrated marked increases in circulating 
NK cells. As with the "moderate dose"  inpatient regimens, 
NK cells  are most  prominently  expanded. By 
contrast, no significant change has occurred in the absolute 
number of T cells. Thus the administration of lower doses of 
IL-2 can selectively activate NK effectors in vivo without the 
severe toxicities  of  high-dose  bolus  IL-2.  Further clinical 
studies will be required to determine the optimal means of 
exploiting these activated NK  cells. 
Manipulation of the graft-versus-leukemia  activity of NK 
cells.  The IL-2/LAK cell trials have involved patients with 
advanced  cancer; cellular immunotherapy  might  be more 
effective in patients with  a  smaller tumor burden. Indeed, 
adjuvant IL-2 therapy has been given to a small number of 
patients with resected stage C colon ~ancer.~"  Most adults 
with acute leukemia in complete remission also have minimal 
residual disease that might be responsive to immune effector 
cells. The presence of endogenously activated NK  cells after 
allogeneic  and autologous  BMT makes these particularly 
attractive settings in which to use the GVL activity of NK 
cells therapeuti~ally.'~~-'~~  However, reluctance to accentuate 
the known toxicities of BMT and fear of aggravating GVHD 
after allogeneic BMT have hindered the  use of IL-2 posttrans- 
plant. Indeed, a child given IL-2 after receiving a histocom- 
patible allograft for metastatic neuroblastoma experienced 
reactivation  of  acute GVHD.222  One group has described 
nine patients treated with  IL-2 after autologous  BMT for 
hematologic  These  patients  were  given 
IL-2 in doses of approximately 1.0 to 2.0  x  lo6  U/m2/day 
for 3 to 5 days. Toxicity was similar to that experienced by 
nontransplant patients given comparable IL-2 therapy.223  As 
expected,  increased  NK cell numbers and enhanced LAK 
activity were evident in the peripheral blood of these patients 
after IL-2 admini~tration.~~~  In contrast to most other IL-2 
trials, however, both activated NK  cells and activated T cells 
appeared to contribute prominently to LAK activity.224 
Our experience  with  prolonged  continuous infusions  of 
IL-2 in patients with advanced solid tumors suggested that 
similar treatment might be tolerable to patients after BMT. 
Furthermore, GVHD has been effectively abrogated in our 
allograft patients by donor marrow treatment with anti-CD6 
MoAbs and complement, without the high incidence of graft 
rejection reported after some methods of T-cell depletion.225 
As  in other transplant series, our patients demonstrate early 
engraftment  of  NK cells,'86 and the latter  appear to  be 
relatively activated in vivo. We have begun a clinical trial of 
IL-2  in  selected  patients  at high  risk  for  relapse  after 
allogeneic or  autologous  BMT; these patients receive  pro- 
longed continuous infusions of  IL-2 in relatively  low doses 
after demonstrating stable neutrophil engraftment. Others 
are  also exploring IL-2 therapy as an  adjunct to BMT.222.226s230 
A minority of patients have an appropriate HLA-matched 
sibling  donor  for  allogeneic  BMT,  and the  rigor  of  the 
procedure precludes  even  autologous  BMT for  many  pa- 
tients. Thus there is considerable interest in manipulating the 
antileukemic activity of  NK cells in clinical contexts other 
than  BMT. Several investigators  have  demonstrated  that 
LAK activity can be generated from the peripheral blood of 
C~56"bright" 
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patients with acute leukemia in remission'80s227s228  or CML  in 
stable phase.zz9  Phase I trials have confirmed the feasibility 
of  IL-2 therapy for patients with acute leukemia.223  Further 
clinical studies of IL-2 in the treatment of  leukemia are in 
progress.223 
CONCLUSIONS 
Less than 15 years ago NK activity was little more than an 
immunologic  curiosity,  even  considered  an  experimental 
artifact by some; today NK  cells are the subject of intensive 
investigation  by a number of laboratories.  Initially  defined 
only by  their spontaneous cytolytic activity,  NK cells can 
now  be  unequivocally  identified  as a  discrete  subset  of 
lymphocytes with characteristic  morphologic, immunopheno- 
typic,  and functional attributes. The availability of  mono- 
clonal antibodies with well-defined reactivity and the use of 
homogeneous  clonal  populations  of  NK cells  have  been 
largely responsible for recent advances in our understanding 
of  these unique effector cells. Although precise knowledge 
regarding the role of NK  cells in normal physiology remains 
elusive, a growing body of  evidence suggests these lympho- 
cytes are involved in the defenses against viral infections, the 
regulation of  hematopoiesis,  and the destruction of malig- 
nant  trlmor  cells.  It is  also  apparent  that the antitumor 
activity of  NK cells can be used therapeutically. The near 
future is likely to bring important new insights into fundamen- 
tal NK  cell biology as well as improved clinical applications 
of these effector cells. 
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